SCHEMBL6038844

SCHEMBL6038844

Cc1ccc(S(=O)(=O)Nc2nccnc2OCc2ccccc2C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.50
MEN1 O00255 4/20 0.50
ALDH1A1 P00352 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MAPT P10636 3/20 0.46
LMNA P02545 1/20 0.46
AR P10275 1/20 0.44
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
POLB P06746 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 2/20 0.42
ALOX12 P18054 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038435 0.88 KMT2A (0.47) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL6038612 0.88 MEN1 (0.53) KMT2AMEN1SMN1; SMN2MAPTGAA
SCHEMBL6038621 0.86 LMNA (0.51) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL6039107 0.86 KMT2A (0.46) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL6038922 0.85 KMT2A (0.45) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL6039144 0.85 AR (0.60) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL6038908 0.84 CCR4 (0.53) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL6038605 0.84 KMT2A (0.54) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL6038494 0.83 KMT2A (0.50) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL6038615 0.83 CCR4 (0.58) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 KMT2A 4190/4885MEN1 2431/4885ALDH1A1 2902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.